Reprogramming Exhausted T Cells, Boosting Cancer Immunotherapy
Summary
USPTO published patent application US20260108496A1 disclosing methods for reviving exhausted T cells and enhancing cancer immunotherapy by inhibiting TGFβR1 and/or BMP4 proteins, or using agonists to rescue functional phenotypes of exhausted T cells. The application was filed on 2023-09-14 under application number 19111688 and published on 2026-04-23. Inventors include Hazem Ghoneim.
“Disclosed are methods and compositions related to reviving the functionality for exhausted T cells and methods of improving immunotherapy by inhibiting T cell exhaustion.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 203 changes logged to date.
What changed
USPTO published patent application US20260108496A1 for methods of reprogramming exhausted T cells and improving immune checkpoint blockade therapy for cancer. The disclosed methods comprise inhibitors of TGFβR1 and/or BMP4 proteins or agonists to rescue the functional phenotype of exhausted T cells. The application includes CPC classifications spanning A61K compound classes and A61P 35/00 (antineoplastic agents).
Affected parties include pharmaceutical and biotechnology companies developing cancer immunotherapies, T cell-based therapies, and checkpoint inhibitors. The patent, once granted, would confer exclusivity over the specific compositions and methods for rescuing exhausted T cell function using TGFβR1/BMP4 modulation in cancer treatment contexts.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR REPROGRAMING EXHAUSTED T CELLS AND BOOSTING IMMUNE CHECKPOINT BLOCKADE THERAPY FOR CANCER
Application US20260108496A1 Kind: A1 Apr 23, 2026
Inventors
Hazem GHONEIM
Abstract
Disclosed are methods and compositions related to reviving the functionality for exhausted T cells and methods of improving immunotherapy by inhibiting T cell exhaustion. In one aspect, the methods and compositions described herein comprise inhibitors of TGFβR1 and/or BMP4 proteins or agonists to rescue the functional phenotype of exhausted T cells.
CPC Classifications
A61K 31/421 A61K 31/167 A61K 31/375 A61K 31/42 A61K 31/4375 A61K 31/444 A61K 31/4709 A61K 31/4985 A61K 31/519 A61K 31/7105 A61K 38/465 A61P 35/00
Filing Date
2023-09-14
Application No.
19111688
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.